Skip to Main Content

Results released Monday from a Phase 2 study of a chronic cough treatment being developed by Bellus Health exceeded the expectations of financial analysts and boost the company’s chances of eventual approval after an earlier trial of the drug had failed.

Bellus said in a press release it expects to meet with the Food and Drug Administration in the second quarter of 2022 and to begin a Phase 3 study of the treatment in the second half of 2022. Roberto Bellini, Bellus’ CEO, said the company is “extremely pleased” with the “compelling” results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment